Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021537 | 0.86 | SIGMAR1 (1.00) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL983664 | 0.85 | CHRM5 (0.71) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL7721235 | 0.83 | CHRM5 (0.72) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL13417680 | 0.81 | CHRM5 (0.70) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL18743787 | 0.79 | CHRM5 (0.72) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL23464917 | 0.77 | CHRM5 (0.75) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL24739915 | 0.76 | SIGMAR1 (0.55) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL23277955 | 0.74 | CHRM5 (0.60) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL24109041 | 0.73 | NPC1 (0.48) | SIGMAR1CHRM5CHRM3NPC1ALDH1A1 | |
| SCHEMBL10101745 | 0.73 | ALDH1A1 (0.71) | SIGMAR1NPC1ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011070131-A1 | 5-AMINO- 4-HYDROXYPENTOYL AMIDES | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10 | SIGMAR1 843/4885CHRM5 1608/4885CHRM3 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.